APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

This trial is testing a drug called APG-1252, either alone or in combination with other cancer drugs, in patients with non-Hodgkin lymphoma (NHL) or peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to treatment. **You may be eligible if...** - You have been diagnosed with relapsed or refractory non-Hodgkin lymphoma or peripheral T-cell lymphoma - You have received at least one prior treatment - You are in reasonably good health (ECOG score 0 or 1) - Your bone marrow, liver, kidney, and heart function are within acceptable ranges - You are willing to use effective contraception during the study **You may NOT be eligible if...** - You have received a stem cell transplant within the past 6 months - You have lymphoma that has spread to the brain - You have significant heart disease or a history of blood clots - You are currently pregnant or breastfeeding - You have uncontrolled infections including active hepatitis B, hepatitis C, or HIV - You have previously been treated with a BCL-xL inhibitor Talk to your doctor to see if this trial is right for you.